A 48-year-old woman with a 3-month history of peptic ulcer disease is prescribed ranitidine 300 mg at night. After 6 weeks of therapy, her symptoms improve significantly. However, she develops gynecomastia and sexual dysfunction. She is concerned about continuing the medication. Which of the following is the most appropriate next step in management?

Explanation

## H₂-Receptor Antagonist Adverse Effects and Management **Key Point:** H₂-receptor antagonists (particularly ranitidine) can cause gynecomastia and sexual dysfunction due to antiandrogenic effects. Switching to a PPI is the most appropriate management. ### Mechanism of Ranitidine-Induced Hormonal Side Effects Ranitidine and other H₂ blockers (especially at higher doses) have weak antiandrogenic properties and can inhibit cytochrome P450 enzymes, leading to: - Gynecomastia (breast tissue proliferation) - Erectile dysfunction and reduced libido - Elevated prolactin levels in some patients These effects are dose-dependent and more common with prolonged use and higher doses. **High-Yield:** PPIs (omeprazole, lansoprazole, pantoprazole) do NOT have significant antiandrogenic effects and are preferred for long-term therapy in patients experiencing H₂ blocker–related sexual dysfunction or gynecomastia. ### Comparison of Acid-Suppressive Agents | Agent | Mechanism | Potency | Gynecomastia Risk | Antiandrogenic | Duration | |-------|-----------|---------|-------------------|----------------|----------| | **Ranitidine** | H₂ antagonist | Moderate | **High** | **Yes** | 8–12 hrs | | **Famotidine** | H₂ antagonist | Moderate | Moderate | Mild | 12 hrs | | **Omeprazole** | PPI | **High** | **Very low** | **No** | 24+ hrs | | **Lansoprazole** | PPI | **High** | **Very low** | **No** | 24+ hrs | | **Aluminum hydroxide** | Antacid | Low | None | No | 1–3 hrs | ### Why Other Options Are Suboptimal **Spironolactone (Option A):** Adding an aldosterone antagonist would not address the underlying antiandrogenic effect of ranitidine and introduces additional side effects (hyperkalemia, further sexual dysfunction). **Dose reduction (Option C):** While reducing the ranitidine dose might help, it compromises ulcer healing efficacy. PPIs are more potent and do not carry the same hormonal risk at any dose. **Antacid monotherapy (Option D):** Aluminum hydroxide alone has poor efficacy for peptic ulcer healing and requires frequent dosing (every 1–3 hours). It is not suitable for long-term management of active ulcer disease. **Clinical Pearl:** Gynecomastia and sexual dysfunction from H₂ blockers are reversible upon discontinuation or switch to a PPI, but may take weeks to months to fully resolve. **Mnemonic:** **H₂ HORMONES** — H₂ blockers can cause Hormonal side effects (gynecomastia, erectile dysfunction); switch to a PPI for long-term therapy.